Approval for the therascreen kras rgq pcr kit, which is to be used as a companion diagnostic for the drug vectibix (panitumumab). this device is indicated for: the therascreen kras rgq pcr kit is a real-time qualitative pcr assay used on the rotor-gene q mdx instrument for the detection of seven somatic mutations in the human kras oncogene, using dna extracted from formalin-fixed paraffin-embedded (ffpe), colorectal cancer (crc) tissue. the therascreen kras rgq pcr kit is intended to aid in the identification of crc patients for treatment with erbitux (cetuximab) and vectibix (panitumumab) based on a kras no mutation detected test result.